(Q56880134)

English

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007

article

In more languages

Statements

scholarly article

0 references

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007 (English)

0 references

World Health Organization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Albert Osterhaus

2

0 references

Marie Paule Kieny

5

object named as

Marie Paule Kieny

0 references

author name string

Marc P. Girard

1

0 references

Yuri Pervikov

3

0 references

Laszlo Palkonyay

4

0 references

language of work or name

0 references

publication date

May 2008

0 references

0 references

26

0 references

20

0 references

2443-2450

0 references

Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Induction of heterosubtypic immunity to influenza virus by intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Sublingual vaccination with influenza virus protects mice against lethal viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Antibody responses after dose-sparing intradermal influenza vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Serum antibody responses after intradermal vaccination against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Dose sparing with intradermal injection of influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Universal influenza A vaccine: optimization of M2-based constructs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.03.006

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56880134&oldid=1829597998"